Background
Infantile hemangioma (IH) is the most common benign tumor of infancy.
For children with IH who require treatment, propranolol and other beta
blockers have been shown to be safe and effective. Although consensus
guidelines for propranolol have been published, anecdotal experience
suggests that there remain variations in management. This study was
performed to document these variations amongst providers and to identify
areas for future research.